While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the drugmaker in a more vulnerable position when rival Eli Lilly ...